Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. It is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
323
Frequently Asked Questions
What is Market Cap of Tarsus Pharmaceuticals Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Tarsus Pharmaceuticals Inc market cap is $2.32B.
What is the 52-week high for Tarsus Pharmaceuticals Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Tarsus Pharmaceuticals Inc 52 week high is $59.76 as of September 20, 2025.
What is the 52-week low for Tarsus Pharmaceuticals Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Tarsus Pharmaceuticals Inc 52 week low is $31.36 as of September 20, 2025.
What is Tarsus Pharmaceuticals Inc stock price today?
Tarsus Pharmaceuticals Inc stock price today is $55.00.
What was Tarsus Pharmaceuticals Inc stock price yesterday?
Tarsus Pharmaceuticals Inc stock price yesterday was $54.03.
What is the PE ratio of Tarsus Pharmaceuticals Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Tarsus Pharmaceuticals Inc’s P/E ratio is -23.62.
What is the Price-to-Book ratio of Tarsus Pharmaceuticals Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Tarsus Pharmaceuticals Inc P/B ratio is 6.9799.
What is the 50-day moving average of Tarsus Pharmaceuticals Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Tarsus Pharmaceuticals Inc 50-day moving average is $49.43.
How many employess does Tarsus Pharmaceuticals Inc has?
